MX2020003079A - Método para detectar proteínas inflamasoma como biomarcadores de trastornos neurológicos. - Google Patents

Método para detectar proteínas inflamasoma como biomarcadores de trastornos neurológicos.

Info

Publication number
MX2020003079A
MX2020003079A MX2020003079A MX2020003079A MX2020003079A MX 2020003079 A MX2020003079 A MX 2020003079A MX 2020003079 A MX2020003079 A MX 2020003079A MX 2020003079 A MX2020003079 A MX 2020003079A MX 2020003079 A MX2020003079 A MX 2020003079A
Authority
MX
Mexico
Prior art keywords
detecting
biomarkers
inflammasome
neurological disorders
brain injury
Prior art date
Application number
MX2020003079A
Other languages
English (en)
Inventor
Robert Keane
Juan Pablo De Rivero Vaccari
W Dalton Dietrich
Helen Bramlett
Original Assignee
Univ Miami
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Miami filed Critical Univ Miami
Publication of MX2020003079A publication Critical patent/MX2020003079A/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/225—Polycarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869—Interleukin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/54—Interleukins [IL]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/54—Interleukins [IL]
    • G01N2333/545—IL-1
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
    • G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
    • G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
    • G01N2333/96466—Cysteine endopeptidases (3.4.22)
    • G01N2333/96469—Interleukin 1-beta convertase-like enzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/285—Demyelinating diseases; Multipel sclerosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2871—Cerebrovascular disorders, e.g. stroke, cerebral infarct, cerebral haemorrhage, transient ischemic event

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Emergency Medicine (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

La presente invención proporciona composiciones y métodos para detectar componentes del inflamasoma en una muestra de un sujeto como marcadores de lesiones cerebrales tales como esclerosis múltiple, accidente cerebrovascular o lesión cerebral traumática. También se describen métodos para utilizar dichos marcadores de inflamasoma para determinar el pronóstico, el tratamiento directo y la monitorización de la respuesta al tratamiento para el sujeto con una lesión cerebral, como esclerosis múltiple, accidente cerebrovascular, deterioro cognitivo leve o lesión cerebral traumática.
MX2020003079A 2017-09-20 2018-09-20 Método para detectar proteínas inflamasoma como biomarcadores de trastornos neurológicos. MX2020003079A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762560963P 2017-09-20 2017-09-20
US201862696549P 2018-07-11 2018-07-11
PCT/US2018/051899 WO2019060516A1 (en) 2017-09-20 2018-09-20 METHOD FOR DETECTION OF INFLAMMASOME PROTEINS AS BIOMARKERS OF NEUROLOGICAL DISORDERS

Publications (1)

Publication Number Publication Date
MX2020003079A true MX2020003079A (es) 2021-01-08

Family

ID=65810943

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020003079A MX2020003079A (es) 2017-09-20 2018-09-20 Método para detectar proteínas inflamasoma como biomarcadores de trastornos neurológicos.

Country Status (11)

Country Link
US (2) US20200333358A1 (es)
EP (1) EP3685169A4 (es)
JP (2) JP2020535401A (es)
KR (2) KR20200088299A (es)
CN (1) CN111356924A (es)
AU (1) AU2018336897A1 (es)
BR (1) BR112020005445A2 (es)
CA (1) CA3076365A1 (es)
MX (1) MX2020003079A (es)
RU (1) RU2020113702A (es)
WO (1) WO2019060516A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112019013463A2 (pt) 2016-12-29 2020-01-07 University Of Miami Método para a modulação da atividade de inflamassoma e da inflamação nos pulmões
US11840565B2 (en) 2016-12-29 2023-12-12 University Of Miami Methods and compositions for treating virus-associated inflammation
JP2023523449A (ja) * 2020-04-27 2023-06-05 ユニバーシティー オブ マイアミ インフラマソーム関連疾患又は病態を処置するための組成物及び方法
CN112816704B (zh) * 2020-12-31 2022-05-24 华中科技大学 用于预测2型糖尿病患者发生mci风险的生物标志物和试剂盒及其应用
CN112684186B (zh) * 2020-12-31 2022-04-01 华中科技大学 用于预测2型糖尿病患者发生mci风险的生物标志物和试剂盒及其应用
WO2023212583A1 (en) * 2022-04-25 2023-11-02 University Of Miami Innate immune proteins as biomarkers for traumatic brain injury in adult and pediatric patients

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8685400B2 (en) * 2007-07-30 2014-04-01 University Of Miami Modulating inflammasome activity and inflammation in the central nervous system
US8759302B2 (en) * 2010-03-16 2014-06-24 Teva Pharmaceutical Industries, Ltd. Methods of treating a subject afflicted with an autoimmune disease using predictive biomarkers of clinical response to glatiramer acetate therapy in multiple sclerosis
IT1406201B1 (it) * 2010-12-10 2014-02-14 Univ Degli Studi Trieste Biomarcatori per la diagnosi della sclerosi multipla
EP2812697B1 (en) * 2012-02-06 2017-03-22 University of Miami Innate immune proteins as biomarkers for cns injury
US10261098B2 (en) * 2014-08-18 2019-04-16 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Biomarkers for diagnosis and management of neuro-immunological diseases
WO2016059571A1 (en) * 2014-10-16 2016-04-21 Novartis Ag Combinations comprising siponimod and laquinimod for the treatment of multiple sclerosis

Also Published As

Publication number Publication date
CA3076365A1 (en) 2019-03-28
RU2020113702A (ru) 2021-10-25
BR112020005445A2 (pt) 2020-09-29
US20200333358A1 (en) 2020-10-22
JP2024069651A (ja) 2024-05-21
WO2019060516A1 (en) 2019-03-28
JP2020535401A (ja) 2020-12-03
KR20230125105A (ko) 2023-08-28
US20230251273A1 (en) 2023-08-10
AU2018336897A1 (en) 2020-04-30
RU2020113702A3 (es) 2022-02-14
EP3685169A1 (en) 2020-07-29
KR20200088299A (ko) 2020-07-22
EP3685169A4 (en) 2021-09-08
CN111356924A (zh) 2020-06-30

Similar Documents

Publication Publication Date Title
MX2020003079A (es) Método para detectar proteínas inflamasoma como biomarcadores de trastornos neurológicos.
CL2021000343A1 (es) Inhibidores peptídicos del receptor de interleucina 23 (divisional de la solicitud n° 201800128)
HK1254665A1 (zh) 預防、改善或治療退行性腦病或認知功能障礙的新型乳酸菌和組合物
MX2018012655A (es) Compuestos y metodos para tratamiento de afecciones neurologicas y cardiovasculares.
MX2018001532A (es) Anticuerpos anti-angptl8 y usos de estos.
EP3299473A4 (en) Method for diagnosing early onset of alzheimer's disease or mild cognitive impairment
PH12015501656A1 (en) Anti-il-33 antibodies and use thereof
EA201692201A1 (ru) Соединения и композиции в качестве агонистов toll-подобного рецептора 7
CA2863417A1 (en) Innate immune proteins as biomarkers for cns injury
WO2011141823A3 (en) Methods of treating and/or preventing cell proliferation disorders with il-17 antagonists
PH12018500887A1 (en) Anti-htra1 antibodies and methods of use thereof
PH12018500578A1 (en) Methods of treating inflammatory diseases
MX2021003515A (es) Compuestos polimorficos y usos de los mismos.
MX2021008289A (es) Composiciones farmaceuticas de levetiracetam de liberacion extendida.
MX2022010954A (es) Dispositivo para la deteccion de proteinas mal plegadas y metodos de uso del mismo.
MX2020006385A (es) Composiciones y metodos para el tratamiento de trastornos neurologicos que comprenden una demencia.
WO2015187521A3 (en) Anti-blys antibodies
WO2016140910A3 (en) Compositions and methods of using anti-mullerian hormone for treatment of infertility
PH12019502694A1 (en) Anti-trkb antibodies
PH12019500434A1 (en) Anti-gm-csf antibodies and uses thereof
EP3274709A4 (en) Biomarkers and methods of diagnosing and prognosing mild traumatic brain injuries
WO2017190834A8 (en) Assay for the diagnosis of a neurological disease
WO2016164468A3 (en) Human monoclonal autoantibodies to adamts13 and uses thereof
GEP20237484B (en) Antibody variants
WO2017095918A3 (en) Methods for treating cancer using rspo3 antagonists